NAC
Nuveen California Quality Municipal Income FundNYSE
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Mon, Nov. 14, 11:13 AM
    • AZ Premium Income Municipal Fund (NYSE:NAZ) - $0.0041.
    • CA Quality Municipal Income Fund (NYSE:NAC) - $0.0076.
    • CA Municipal Value Fund (NYSE:NCA) - $0.0004.
    • OH Quality Income Municipal Fund (NYSE:NUO) - $0.0007.
    • TX Quality Income Municipal Fund (NYSE:NTX) - $0.0005.
    • Payable Dec. 1; for shareholders of record Nov. 21 ex-div Nov. 17.
    • Press Release
    | Mon, Nov. 14, 11:13 AM
  • Wed, Nov. 9, 6:10 PM
    • Nuveen CA Dividend Advantage Muni. Fund (NYSE:NAC) declares $0.0685/share monthly dividend, 9.8% increase from prior dividend of $0.0624.
    • Forward yield 5.56%
    • Payable Dec. 30; for shareholders of record Dec. 15; ex-div Dec. 13.
    | Wed, Nov. 9, 6:10 PM
  • Fri, Oct. 7, 8:39 AM
    • Nuveen CA Dividend Advantage Municipal Fund (NYSE:NAC) - $0.0685.
    • Nuveen CA AMT-Free Municipal Income Fund (NYSE:NKX) - $0.0670.
    • Nuveen CA Municipal Value Fund (NYSE:NCA) - $0.0360.
    • Nuveen CA Dividend Advantage Municipal Fund 2 (NYSEMKT:NVX) - $0.0625.
    • Nuveen CA Dividend Advantage Municipal Fund 3 (NYSEMKT:NZH) - $0.0635.
    • Nuveen CA Select Tax-Free Income Portfolio (NYSE:NXC) - $0.0525.
    • Nuveen CA Municipal Value Fund 2 (NYSE:NCB) - $0.0600.
    • Payable Nov. 1; for shareholders of record Oct. 14; ex-div Oct. 12.
    • Press Release
    | Fri, Oct. 7, 8:39 AM
  • Wed, Sep. 14, 11:27 AM
    • Array BioPharma (ARRY) reaches agreement with the FDA on the design of a Phase 3 clinical trial, BEACON CRC, assessing the combination of encorafenib and Eli Lilly's (LLY +0.3%Erbitux (cetuximab), with or without binimetinib, in patients with BRAF-positive colorectal cancer (CRC) who have previously received first- or second-line systemic therapy.
    • BEACON CRC is an open-label study that will randomize 615 subjects 1:1:1 to receive either triplet therapy (encorafenib, Erbitux, binimetinib), doublet therapy (encorafenib, Erbitux) or control (irinotecan-based therapy and Erbitux). The primary endpoint is overall survival (OS) of the triplet therapy compared to control. Secondary endpoints will compare the efficacy of the doublet therapy to control and the triplet therapy to the doublet therapy, in addition to progression-free survival, objective response rate, duration of response, safety and tolerability. Patient enrollment should be completed in 2018.
    • Encorafenib is a BRAF inhibitor acquired from Novartis (NVX +0.8%) in early 2015. Cetuximab is an EGFR inhibitor. Binimetinib is a small molecule MEK inhibitor.
    | Wed, Sep. 14, 11:27 AM | 6 Comments
  • Tue, Sep. 13, 10:44 AM
    • Nuveen CA Dividend Advantage Municipal Fund (NYSE:NAC) - $0.0685.
    • Nuveen CA AMT-Free Municipal Income Fund (NYSE:NKX) - $0.0670.
    • Nuveen CA Municipal Value Fund (NYSE:NCA) - $0.0360.
    • Nuveen CA Dividend Advantage Municipal Fund 2 (NYSEMKT:NVX) - $0.0625.
    • Nuveen CA Dividend Advantage Municipal Fund 3 (NYSEMKT:NZH) - $0.0635.
    • Nuveen CA Select Tax-Free Income Portfolio (NYSE:NXC) - $0.0525.
    • Nuveen CA Municipal Value Fund 2 (NYSE:NCB) - $0.0600.
    • Payable Oct. 3; for shareholders of record Sept. 15; ex-div Sept. 13.
    • Press Release
    | Tue, Sep. 13, 10:44 AM
  • Wed, Jun. 15, 3:32 AM
    • California has overtaken France as the world’s sixth-largest economy, growing by 4.1% in 2015.
    • The most-populous U.S. state, with a gross domestic product of $2.5T, has also eclipsed recession-plagued Brazil.
    • "This is the result of both good growth in California and exchange-rate movements of the dollar vs. other currencies," said Irena Asmundson, chief economist of the California Department of Finance.
    • ETFs: PCK, VCV, NAC, BFZ, PZC, PCQ, MCA, NKX, MUC, CMF, MYC, CCA, NZH, EVM, NCA, NVX, CEV, EIA, AKP, PWZ, BJZ, NXC, CXA, NBW, NCB
    | Wed, Jun. 15, 3:32 AM | 20 Comments
  • Mon, May 16, 10:44 AM
    • Mabtech Ltd., a biosimilar development and commercialization partner with Sorrento Therapeutics (SRNE +3.1%), completes a successful Phase 2/3 clinical trial in China assessing Sorrento's STI-004, a biosimilar antibody of Roche (OTCQX:RHHBY +0.8%) and Novartis' (NVX +0.2%) asthma and urticaria med Xolair (omalizumab).
    • STI-004 is one of four monoclonal antibodies licensed by Sorrento from Mabtech last year for the territories of North America, Europe and Japan.
    • Previously: Sorrento inks biosimilar antibody deal with China's Mabtech (Aug. 3, 2015)
    | Mon, May 16, 10:44 AM
  • Jul. 3, 2015, 3:17 AM
    • Marking another sign of the state's financial recovery, the one-notch upgrade to "AA-" from "A+" gives California GO debt the highest rating from S&P since 2000 - when the dot-com bust hammered the state's economy.
    • California's new budget, "marks another step forward in the state's journey toward improved fiscal sustainability," said the agency's report.
    • California now outranks Illinois and New Jersey and is tied with Michigan and Pennsylvania.
    • ETFs: PCK, VCV, BFZ, PCQ, PZC, MCA, NAC, NKX, MUC, CMF, MYC, CCA, NZH, EVM, PWZ, AKP, NCA, NVX, CEV, EIA, BJZ, CXA, NXC, NCB, NBW
    | Jul. 3, 2015, 3:17 AM | 8 Comments